Project Grant R15CA305114
Award Date
7/15/25
Completion Date
6/30/28
Dollars Obligated
$545K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program for Cancer Cause and Prevention Research (CFDA 93.393), supports research to elucidate the roles and regulatory mechanisms of the protein APE1 in the ATR DNA damage response signaling pathway. The $342,569 award, effective March 1, 2025 through February 28, 2030, will enable researchers at the University of North Carolina at Charlotte to investigate how APE1 forms liquid-liquid phase separations in...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $541,682 to The Trustees of Columbia University in the City of New York for a 5-year period from July 3, 2024 to June 30, 2029. The project aims to better understand the mechanisms responsible for the assembly of DNA repair domains in cancer cells and evaluate the consequences of these domains following treatment with chemotherapeutic drugs....
This Project Grant award of $514,582, provided by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of North Carolina at Chapel Hill, supports research on the role of APOBEC3 enzymes in bladder cancer initiation, progression, and treatment resistance. The research aims to gain a better understanding of how APOBEC3 promotes squamous differentiation in bladder tumors and explore whether co-inhibition of the IL1A pathway can be leveraged to reverse...
The National Cancer Institute (NCI) awarded a $487,393 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research in New York, NY, effective December 1, 2024 through November 30, 2029. The grant supports research to determine the role of RAD52, HELQ, and POLQ proteins in backup DNA double-strand break repair pathways, which are critical for the survival of homologous recombination deficient (HRD) cancer cells. The research aims to...
This Project Grant award of $513,542 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to define the role of the p53 protein in regulating chaperone-mediated autophagy (CMA) and the impact on tumor development. The research aims to elucidate the mechanisms by which p53 activates CMA, a selective form of autophagy, and how this regulation of CMA and cellular metabolism contributes to p53's tumor suppressive functions. The award was granted to The...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
This Project Grant award of $432,614.00 from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research at Duke University to investigate the relationship between chromosomal instability, 17p loss, and NDE1 dependence in cancer cells. The goal is to define the genetic dependencies resulting from these factors and assess the therapeutic potential of targeting NDE1 in cancers with increased chromosomal instability and 17p loss. The award period...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $145,656.00 to the University of North Carolina at Chapel Hill to investigate the mutagenic effects of the APOBEC3A and APOBEC3B enzymes in urothelial carcinoma, a common and deadly form of bladder cancer. The project aims to elucidate the driver of APOBEC-induced mutagenesis, compare the promotion of intratumoral heterogeneity by the two enzymes, and determine their influence on...
This $2,556,071 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to The University of Texas Health Science Center at San Antonio. The award supports a collaborative research program focused on elucidating the mechanisms by which the BRCA1-BARD1 and BRCA2 tumor suppressors promote homologous recombination (HR) DNA repair, and how this is negatively regulated by the 53BP1 axis to favor the use of...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...